Dopamine D1 Receptor Agonist A-68930 Inhibits NLRP3 Inflammasome Activation and Protects Rats from Spinal Cord Injury-Induced Acute Lung Injury

W Jiang,M Li,F He,Z Bian,J Liu,Q He,X Wang,T Sun,L Zhu
DOI: https://doi.org/10.1038/sc.2016.52
2016-01-01
Spinal Cord
Abstract:Study design: Randomized experimental study. Objectives: The study aimed to investigate the therapeutic efficacy and molecular mechanisms of A-68930 in a rat model of spinal cord injury (SCI)–induced acute lung injury (ALI). Setting: China. Methods: The influences of A-68930 on the pulmonary edema, histological changes, proinflammatory cytokines levels, myeloperoxidase (MPO) activity and NLRP3 inflammasome protein expression were estimated. Results: SCI significantly promoted NLRP3 inflammasome activation, increased proinflammatory cytokine productions and MPO activity, and induced pulmonary edema and tissue damage in the SCI group as compared with the control group. A-68930 administration significantly inhibited NLRP3 inflammasome activation and reduced inflammatory cytokines levels and MPO activity. Moreover, A-68930 administration attenuated pulmonary edema and histopathology. Conclusion: Our experimental findings indicated that A-68930 exhibited a protective effect on SCI-induced ALI by the alleviations of inflammatory response with the inhibition NLRP3 inflammasome activation 72 h post injury. The present study indicated that A-68930 could be a potentially efficient therapeutic strategy for the treatment of SCI-induced ALI.
What problem does this paper attempt to address?